TY - JOUR
T1 - Characterisation of the Dynamic Interactions between Complex N-Glycans and Human CD22
AU - Di Carluccio, Cristina
AU - Crisman, Enrique
AU - Manabe, Yoshiyuki
AU - Forgione, Rosa Ester
AU - Lacetera, Alessandra
AU - Amato, Jussara
AU - Pagano, Bruno
AU - Randazzo, Antonio
AU - Zampella, Angela
AU - Lanzetta, Rosa
AU - Fukase, Koichi
AU - Molinaro, Antonio
AU - Crocker, Paul R.
AU - Martín-Santamaría, Sonsoles
AU - Marchetti, Roberta
AU - Silipo, Alba
N1 - Funding Information: H2020 Marie Skłodowska-Curie Actions. Grant Numbers: 642157, 814102; Mizutani Foundation for Glycoscience. Grant Number: 2014-2015
PY - 2020/1/15
Y1 - 2020/1/15
N2 - CD22 (Siglec-2) is a B-cell surface inhibitory protein capable of selectively recognising sialylated glycans, thus dampening autoimmune responses against self-antigens. Here we have characterised the dynamic recognition of complex-type N-glycans by human CD22 by means of orthogonal approaches including NMR spectroscopy, computational methods and biophysical assays. We provide new molecular insights into the binding mode of sialoglycans in complex with h-CD22, highlighting the role of the sialic acid galactose moieties in the recognition process, elucidating the conformational behaviour of complex-type N-glycans bound to Siglec-2 and dissecting the formation of CD22 homo-oligomers on the B-cell surface. Our results could enable the development of additional therapeutics capable of modulating the activity of h-CD22 in autoimmune diseases and malignancies derived from B-cells.
AB - CD22 (Siglec-2) is a B-cell surface inhibitory protein capable of selectively recognising sialylated glycans, thus dampening autoimmune responses against self-antigens. Here we have characterised the dynamic recognition of complex-type N-glycans by human CD22 by means of orthogonal approaches including NMR spectroscopy, computational methods and biophysical assays. We provide new molecular insights into the binding mode of sialoglycans in complex with h-CD22, highlighting the role of the sialic acid galactose moieties in the recognition process, elucidating the conformational behaviour of complex-type N-glycans bound to Siglec-2 and dissecting the formation of CD22 homo-oligomers on the B-cell surface. Our results could enable the development of additional therapeutics capable of modulating the activity of h-CD22 in autoimmune diseases and malignancies derived from B-cells.
KW - molecular recognition
KW - N-glycans
KW - NMR spectroscopy
KW - sialic acids
KW - Siglecs
UR - http://www.scopus.com/inward/record.url?scp=85074393287&partnerID=8YFLogxK
U2 - 10.1002/cbic.201900295
DO - 10.1002/cbic.201900295
M3 - Article
C2 - 31095840
AN - SCOPUS:85074393287
SN - 1439-4227
VL - 21
SP - 129
EP - 140
JO - ChemBioChem
JF - ChemBioChem
IS - 1-2
ER -